-
Deferoxamine Mesylate at the Ferroptosis Frontier
2026-09-03
Deferoxamine mesylate is more than a conventional iron-chelating agent: it is a translational probe for testing how labile iron, oxidative stress, ferroptosis, and hypoxia signaling interact. This article connects FDXR-related disease biology with practical research design, cancer models, tissue protection, and future biomarker strategies.
-
PCN Suppresses Hippocampal CYP and Neurotoxicity
2026-09-03
A 2025 mouse study reports that Pregnenolone-16α-carbonitrile suppresses hippocampal CYP3A11 and CYP2B10 despite inducing these enzymes in the liver. The protective effect against phenytoin-associated neuronal injury was linked to glucocorticoid receptor signaling rather than the canonical PXR pathway, highlighting tissue-specific interpretation of PCN responses.
-
Mithramycin A Workflows for Transcription Studies
2026-09-02
Mithramycin A converts G-C-rich DNA recognition into a practical perturbation tool for transcription, c-myc regulation, and differentiation assays. This workflow connects leukemia models with a carefully bounded extension of the miR-24-3p/Sp1/PI3K findings in doxorubicin-related cardiac injury research.
-
TXA–NO–Propolis Dressings for Trauma Hemostasis
2026-09-02
The reference study presents a bilayer wound dressing that combines Tranexamic Acid, an antifibrinolytic agent, with the nitric oxide donor SNAP and antibacterial propolis. Its formulation stabilized fibrin while producing substantial reductions in bacterial colony formation, supporting a materials-based strategy for addressing hemorrhage and infection together.
-
Demethyleneberberine in Neurodegeneration: Mechanisms
2026-09-01
The 2022 Molecular Biology Reports review frames Demethyleneberberine (DMB), a berberine metabolite, as a hypothesis-generating neuroprotective compound with antioxidant, anti-inflammatory, mitochondrial, and signaling effects. Its main value is the integration of NF-κB, MAPK, and AMPK mechanisms while clearly showing that direct disease-specific validation remains necessary.
-
Melittin for GPCR and Cancer Biology Research
2026-09-01
Melittin is a bioactive peptide tool for separating Gs- and Gi-linked signaling from downstream effects such as migration, apoptosis, and ferroptosis. This workflow translates glioblastoma findings into practical assay designs while emphasizing fresh preparation, dose-finding, and controls for membrane-associated toxicity.
-
Palbociclib (PD0332991): CDK4/6 Research Guide
2026-08-31
Palbociclib (PD0332991) is a selective CDK4/6 inhibitor that suppresses Rb phosphorylation and produces G0/G1 cell-cycle arrest in responsive cancer models. This guide connects potency, breast cancer research, renal cell carcinoma research, assay design, storage, and evidence limits for the A8335 isethionate product.
-
(S)-(+)-Dimethindene maleate: M2 Workflow
2026-08-31
This dossier-based guide explains how to use (S)-(+)-Dimethindene maleate as an M2 muscarinic receptor antagonist while accounting for its additional H1 antagonist activity, water solubility, and solution-handling limits. It is intended for controlled pharmacological research, not diagnostic, therapeutic, or medical use.
-
Surface-Cleaned BPNSs in AKI Ferroptosis
2026-08-30
A 2026 Theranostics study shows that hydrogen-reduced, surface-cleaned black phosphorus nanosheets can chelate labile iron, suppress tubular ferroptosis, and moderate macrophage activation in acute kidney injury. The work links nanosheet surface chemistry with renal biodistribution and ferroptosis–immune crosstalk, providing a framework for multimodal AKI intervention.
-
LGK-974: Reading Wnt Signals in Context
2026-08-29
LGK-974 is a potent PORCN inhibitor for dissecting how secreted Wnt ligands control pathway activity in cancer and developmental models. This guide connects its molecular pharmacology with recent hemichordate evidence to improve assay timing, endpoint selection, and interpretation.
-
Platinum Nanotherapeutics Trigger an Intracellular ROS Storm
2026-08-28
Liu and colleagues developed carrier-platin, a poly(amino acids)-based formulation containing ultrasmall platinum nanoparticles that rapidly elevates intracellular reactive oxygen species. The resulting cancer-cell death occurs independently of DNA damage and is distinct from classical apoptosis and ferroptosis, offering a mechanistic rationale for activity against multidrug-resistant tumors.
-
TSPAN18–STIM1 Signaling in Prostate Cancer Bone Metastasis
2026-08-28
Zhou et al. identified TSPAN18 as a regulator of STIM1 stability, showing that it protects STIM1 from TRIM32-mediated ubiquitination and sustains store-operated calcium entry. The resulting TSPAN18–STIM1–Ca2+ axis promoted prostate cancer migration, invasion, and bone metastasis, while clinical associations supported its relevance as a potential disease marker and therapeutic target.
-
EZ Cap™ Human PTEN mRNA: Research Guide
2026-08-27
EZ Cap™ Human PTEN mRNA (ψUTP) is an in vitro transcribed mRNA designed for controlled restoration of human PTEN expression in mammalian research models. Its Cap 1 structure, pseudouridine triphosphate, and poly(A) tail support mRNA stability enhancement, while published nanoparticle work connects PTEN expression with PI3K/Akt signaling pathway inhibition in trastuzumab-resistant breast cancer models.
-
TCF25, Lysosomal Acidification, and Glucose Starvation
2026-08-27
Ren et al. identify TCF25 as a nutrient-stress regulator that links glucose deprivation to V-ATPase-dependent lysosomal acidification, autophagy, and ATP maintenance. The study also shows that prolonged TCF25 activity drives ferritinophagy, lysosomal membrane permeability, and lysosome-dependent cell death, while TCF25 deficiency protects mice from hepatic ischemia-reperfusion injury.
-
EV-Transferred ACLY Drives TAMs in HCC
2026-08-26
A 2026 Advanced Science study identifies extracellular vesicle transfer of ATP-citrate lyase as a metabolic mechanism that converts monocytes into immunosuppressive tumor-associated macrophages in hepatocellular carcinoma. Engineered CD81-decorated vesicles carrying either ACLY or its inhibitor establish a causal link between vesicle cargo, palmitate production, immune-checkpoint stability, tumor progression, and response to PD-1/PD-L1 blockade.